A system for the electrochemical detection of triglyceride levels includes a test strip including an electrode and a counter electrode, the electrode and counter electrode located proximate to a sample reception area; and a coating on one of the electrode and counter electrode, the coating including a reagent coating for triglycerides.

The present invention addresses the problem of providing: a glucose dehydrogenase; a polynucleotide encoding the enzyme; a method for producing the enzyme; a method for measuring glucose using the enzyme; a measurement reagent composition; and a biosensor. The present invention pertains to a protein that has any of amino acid sequences (a), (b) and (c) and has a glucose dehydrogenase activity, etc.: (a) an amino acid sequence represented by SEQ ID NO: 3, 6, 15 or 16; (b) an amino acid sequence derived from the amino acid sequence represented by SEQ ID NO: 3, 6, 15 or 16 by deleting, substituting or adding 1-3 amino acids; and (c) an amino acid sequence having 90% or more identity to the amino acid sequence represented by SEQ ID NO: 3 or 15 or 85% or more identity to the amino acid sequence represented by SEQ ID NO: 6 or 16.

Devices, kits, and assays are provided for the testing and monitoring of hemoglobin, anemia, glucose-6-phoshate dehydrogenase, and glucose-6-phosphate dehydrogenase deficiency in an individual.

The present invention includes a method of identifying 2-hydroxygluterate (2-hg) metabolites in a sample comprising: obtaining the sample from a patient; extracting the 2-hydroxygluterate (2-hg) metabolites from the sample without modifying a chiral center of the 2-hg metabolites; separating the one or more 2-hg metabolites in the sample using a chiral gas chromatography capillary column; and quantitating an amount of 2-hg metabolites in the sample using mass spectrometry.

The present disclosure relates generally to compositions and methods for diagnosing or predicting autism spectrum disorder (ASD). The methods are based on the discovery that certain genes, such as SOD2, OXT, GPER, and ERRα, have different expression levels in CD34+ cells or MNCs in ASD patients as compared to individuals not having ASD. Once the ASD patient is identified or predicted, compositions and methods are also provided for preventing or treating the ASD.

The present disclosure provides methods, compositions and kits for measuring activity of a frataxin (FXN) protein, e.g., an FXN fusion protein. The present invention also provides methods for identifying compounds capable of modulating activity of an FXN protein, e.g., an FXN fusion protein.

Microbes expressing cholesterol oxidoreductase (COR) proteins, methods of engineering the microbes expressing COR proteins, compositions and methods of using the microbes are provided.

Provided herein are methods of detecting or determining aging and/or oxidative damage in tissue, including placental tissue, skin, kidney and brain tissue. One embodiment provides a method for detecting or determining aging in body tissue, comprising measuring one or more markers of aldehyde oxidase 1 (AOX1) expression or activity in a biological sample, wherein the level of AOX1 expression or activity, or of the one or more markers, is indicative of aging in the tissue. Also provided herein are methods of treating a disease or condition associated with ageing or oxidative damage in one or more cells or tissues, comprising administering to a subject in need thereof an inhibitor of AOX1.

The disclosed technology relates to chemical entities for the detection of wounds, e.g., chronic wounds or infected wounds, including compositions, substrates, kits, dressing materials, and articles, and systems containing such compounds. The disclosed technology further relates to methods of using these compositions, kits and systems in diagnostic assays, and in the diagnosis and/or detection of chronic or infected wounds based on enzymatic action on specific moieties and/or reaction sites. The disclosed technology additionally relates to detection of pathogenic, e.g., bacterial and/or viral substances, such as enzymes and substrates, at the wound situs. Additional disclosure relates to methods of characterizing wounds based on expression of a plurality of markers and using such information to treat, manage, and follow-up patients suffering from chronic or infected wounds.

This disclosure relates to a screening test method, device, and kit for mucosal carbohydrates and associated conditions including, cancerous and precancerous conditions. Specifically, the method tests abnormal carbohydrates in mucus or body fluid using reagents of galactose oxidase, and Schiff's Reagent. The screening test method, device, and kit provides improved accuracy, and minimizes handling procedures. This disclosure further relates to the use of the device or kit in a healthcare facility for an initial evaluation for cancerous and precancerous conditions.